NurExone Biologic Inc (NRX) Income Statement & Earnings

0.620
0.0000.00%

15min DelayMarket Closed Jan 14 16:00 ET

56.22MMarket Cap-5.49P/E (TTM)

NurExone Biologic Inc (NRX) Income Statement

Quarterly+Annual

YOY

Hide blank lines

(Q3)Sep 30, 2025

(Q2)Jun 30, 2025

(Q1)Mar 31, 2025

(FY)Dec 31, 2024

(Q4)Dec 31, 2024

(Q3)Sep 30, 2024

(Q2)Jun 30, 2024

(Q1)Mar 31, 2024

(FY)Dec 31, 2023

(Q4)Dec 31, 2023

Total revenue

Operating revenue

--0

Cost of revenue

Gross profit

Operating expense

14.09%1.47M

38.03%1.82M

84.78%1.7M

36.97%5.01M

107.26%1.48M

10.40%1.29M

24.53%1.32M

27.96%920K

-34.00%3.66M

-14.86%716K

Selling and administrative expenses

-2.43%763K

38.55%1.13M

55.68%1.08M

48.50%3.11M

112.95%822K

2.62%782K

34.66%812K

101.45%695K

-49.35%2.1M

-12.67%386K

-General and administrative expense

-2.43%763K

38.55%1.13M

55.68%1.08M

48.50%3.11M

112.95%822K

2.62%782K

34.66%812K

101.45%695K

-49.35%2.1M

-12.67%386K

Research and development costs

39.76%703K

37.20%697K

174.67%618K

21.22%1.87M

104.53%632K

25.12%503K

11.16%508K

-39.84%225K

10.78%1.54M

-19.74%309K

Depreciation amortization depletion

----

42.86%30K

----

50.00%21K

----

-Depreciation and amortization

----

42.86%30K

----

50.00%21K

----

Operating profit

-14.09%-1.47M

-38.03%-1.82M

-84.78%-1.7M

-36.97%-5.01M

-107.26%-1.48M

-10.40%-1.29M

-24.53%-1.32M

-27.96%-920K

34.00%-3.66M

14.86%-716K

Net non-operating interest income (expenses)

-97.14%1K

-380.00%-24K

1,200.00%22K

-26.19%31K

0.00%3K

483.33%35K

-125.00%-5K

-114.29%-2K

333.33%42K

-99.16%3K

Non-operating interest income

-43.24%21K

-43.75%9K

450.00%33K

----

516.67%37K

-38.46%16K

--6K

----

Non-operating interest expense

900.00%20K

57.14%33K

37.50%11K

433.33%16K

133.33%1K

--2K

250.00%21K

--8K

-90.91%3K

---3K

Total other finance cost

----

-4.44%-47K

----

114.29%2K

-200.00%-45K

----

Other net income (expenses)

-170.83%-65K

99.08%-24K

Gain on sale of security

----

-1,050.00%-23K

----

99.57%-2K

----

Other non-operating income (expenses)

----

-90.91%-42K

----

66.67%-22K

----

Income before tax

-17.20%-1.47M

-39.32%-1.85M

-82.00%-1.68M

-38.58%-5.04M

-109.77%-1.55M

-7.94%-1.25M

-27.40%-1.33M

-30.78%-922K

55.45%-3.64M

27.32%-737K

Income tax

Earnings from equity interest net of tax

Net income

-17.20%-1.47M

-39.32%-1.85M

-82.00%-1.68M

-38.58%-5.04M

-109.77%-1.55M

-7.94%-1.25M

-27.40%-1.33M

-30.78%-922K

55.45%-3.64M

27.32%-737K

Net income continuous operations

-17.20%-1.47M

-39.32%-1.85M

-82.00%-1.68M

-38.58%-5.04M

-109.77%-1.55M

-7.94%-1.25M

-27.40%-1.33M

-30.78%-922K

55.45%-3.64M

27.32%-737K

Noncontrolling interests

Net income attributable to the company

-17.20%-1.47M

-39.32%-1.85M

-82.00%-1.68M

-38.58%-5.04M

-109.77%-1.55M

-7.94%-1.25M

-27.40%-1.33M

-30.78%-922K

55.45%-3.64M

27.32%-737K

Preferred stock dividends

Other under preferred stock dividend

Net income attributable to common stockholders

-17.20%-1.47M

-39.32%-1.85M

-82.00%-1.68M

-38.58%-5.04M

-109.77%-1.55M

-7.94%-1.25M

-27.40%-1.33M

-30.78%-922K

55.45%-3.64M

27.32%-737K

Diluted earnings per share

0.00%-0.02

-9.09%-0.024

-43.75%-0.023

4.94%-0.077

-13.33%-0.017

23.08%-0.02

8.33%-0.022

0.00%-0.016

62.50%-0.081

0.00%-0.015

Basic earnings per share

0.00%-0.02

-9.09%-0.024

-43.75%-0.023

4.94%-0.077

-13.33%-0.017

23.08%-0.02

8.33%-0.022

0.00%-0.016

62.50%-0.081

0.00%-0.015

Dividend per share

Accounting Standards

US-GAAP

Audit Opinions

Unqualified Opinion with Explanatory Notes

	(Q3)Sep 30, 2025	(Q2)Jun 30, 2025	(Q1)Mar 31, 2025	(FY)Dec 31, 2024	(Q4)Dec 31, 2024	(Q3)Sep 30, 2024	(Q2)Jun 30, 2024	(Q1)Mar 31, 2024	(FY)Dec 31, 2023	(Q4)Dec 31, 2023
Total revenue	0	0	0	0	0	0	0	0	0	0
Operating revenue	--0	--0	--0	--0	--0	--0	--0	--0	--0	--0
Cost of revenue
Gross profit
Operating expense	14.09%1.47M	38.03%1.82M	84.78%1.7M	36.97%5.01M	107.26%1.48M	10.40%1.29M	24.53%1.32M	27.96%920K	-34.00%3.66M	-14.86%716K
Selling and administrative expenses	-2.43%763K	38.55%1.13M	55.68%1.08M	48.50%3.11M	112.95%822K	2.62%782K	34.66%812K	101.45%695K	-49.35%2.1M	-12.67%386K
-General and administrative expense	-2.43%763K	38.55%1.13M	55.68%1.08M	48.50%3.11M	112.95%822K	2.62%782K	34.66%812K	101.45%695K	-49.35%2.1M	-12.67%386K
Research and development costs	39.76%703K	37.20%697K	174.67%618K	21.22%1.87M	104.53%632K	25.12%503K	11.16%508K	-39.84%225K	10.78%1.54M	-19.74%309K
Depreciation amortization depletion	----	----	----	42.86%30K	----	----	----	----	50.00%21K	----
-Depreciation and amortization	----	----	----	42.86%30K	----	----	----	----	50.00%21K	----
Operating profit	-14.09%-1.47M	-38.03%-1.82M	-84.78%-1.7M	-36.97%-5.01M	-107.26%-1.48M	-10.40%-1.29M	-24.53%-1.32M	-27.96%-920K	34.00%-3.66M	14.86%-716K
Net non-operating interest income (expenses)	-97.14%1K	-380.00%-24K	1,200.00%22K	-26.19%31K	0.00%3K	483.33%35K	-125.00%-5K	-114.29%-2K	333.33%42K	-99.16%3K
Non-operating interest income	-43.24%21K	-43.75%9K	450.00%33K	----	----	516.67%37K	-38.46%16K	--6K	----	----
Non-operating interest expense	900.00%20K	57.14%33K	37.50%11K	433.33%16K	133.33%1K	--2K	250.00%21K	--8K	-90.91%3K	---3K
Total other finance cost	----	----	----	-4.44%-47K	----	----	----	114.29%2K	-200.00%-45K	----
Other net income (expenses)				-170.83%-65K					99.08%-24K
Gain on sale of security	----	----	----	-1,050.00%-23K	----	----	----	----	99.57%-2K	----
Other non-operating income (expenses)	----	----	----	-90.91%-42K	----	----	----	----	66.67%-22K	----
Income before tax	-17.20%-1.47M	-39.32%-1.85M	-82.00%-1.68M	-38.58%-5.04M	-109.77%-1.55M	-7.94%-1.25M	-27.40%-1.33M	-30.78%-922K	55.45%-3.64M	27.32%-737K
Income tax
Earnings from equity interest net of tax
Net income	-17.20%-1.47M	-39.32%-1.85M	-82.00%-1.68M	-38.58%-5.04M	-109.77%-1.55M	-7.94%-1.25M	-27.40%-1.33M	-30.78%-922K	55.45%-3.64M	27.32%-737K
Net income continuous operations	-17.20%-1.47M	-39.32%-1.85M	-82.00%-1.68M	-38.58%-5.04M	-109.77%-1.55M	-7.94%-1.25M	-27.40%-1.33M	-30.78%-922K	55.45%-3.64M	27.32%-737K
Noncontrolling interests
Net income attributable to the company	-17.20%-1.47M	-39.32%-1.85M	-82.00%-1.68M	-38.58%-5.04M	-109.77%-1.55M	-7.94%-1.25M	-27.40%-1.33M	-30.78%-922K	55.45%-3.64M	27.32%-737K
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders	-17.20%-1.47M	-39.32%-1.85M	-82.00%-1.68M	-38.58%-5.04M	-109.77%-1.55M	-7.94%-1.25M	-27.40%-1.33M	-30.78%-922K	55.45%-3.64M	27.32%-737K
Diluted earnings per share	0.00%-0.02	-9.09%-0.024	-43.75%-0.023	4.94%-0.077	-13.33%-0.017	23.08%-0.02	8.33%-0.022	0.00%-0.016	62.50%-0.081	0.00%-0.015
Basic earnings per share	0.00%-0.02	-9.09%-0.024	-43.75%-0.023	4.94%-0.077	-13.33%-0.017	23.08%-0.02	8.33%-0.022	0.00%-0.016	62.50%-0.081	0.00%-0.015
Dividend per share
Accounting Standards	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP
Audit Opinions	--	--	--	Unqualified Opinion with Explanatory Notes	--	--	--	--	Unqualified Opinion with Explanatory Notes	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"